A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase
This randomized phase IIB trial studies imatinib mesylate at two different doses and
dasatinib to see how well they work in treating patients with previously untreated chronic
phase chronic myelogenous leukemia. Imatinib mesylate or dasatinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society